Full Title: Future Focus: The Current and Future U.S. Market for Myelodysplastic Syndrome
Free Bonus Reports When you invest in the MDS report you may pick any 10 Cancer Highlights reports from this list for free (Value: $26,000 USD)
Myelodysplastic syndromes (MDS) are diseases of the blood cells. These diseases can have varying degrees of impact on a person’s life ranging from mild anemia to acute myelogenous leukemia. MDS is an increasingly visible and growing disease that is not well covered by existing data sources. This unique new report was produced to provide companies with an impartial assessment of the current population and clinical landscape of MDS. Emerging new drugs to treat MDS may also show promising opportunities for other indications such as leukemia. This report reviews the current medical and market climates for MDS and assesses future treatment(s) and potential opportunities arising from market evolution. Topics Include - Disease Background – discussion on the disease state and key classification systems
- Patient Population – U.S. estimates for incidence, survival, leukemic progression, and prevalence; discussion of prognosis and IPSS risk groups
- Clinical Management – current and future looks at clinical management for MDS patients by IPSS risk group, including supportive care, chemotherapy, and transplantation
- Emerging Technologies – market overview, timeline, and profiles of new agents
- Competitive Landscape – current market value, competitors, and forecasts to 2015
Profiled Current / Emerging MDS Agents* - Clolar
- Cloretazine
- Dacogen
- Revlimid
- Sarasar
- Thalomid
- Trisenox
- Troxaty
- Vidaza
- Zarnestra
Unique Features of This Report - Forward-looking review and analysis of the rapidly evolving MDS drug market in the United States
- High quality epidemiology using rigorous MattsonJack DaVinci modeling
- Illumination of prospects for new drug development for treating MDS patients
- Practicing physician opinion on current treatment and use of new therapies for these diseases
- Projections of the MDS market based on primary and secondary information with forecasts through 2015
- Discussion of hurdles and opportunities for entering this market
- Identification and analysis of strategies for winning in this market
Benefits Marketing and brand team managers, and market research analysts in both major pharmaceutical and biotech companies will find this report invaluable for determining the size of the current and future MDS market; sales forecasting new products; and successful strategic planning and business development opportunities in the future MDS market. Our report will enable you to: - Be abreast of thought-leader and community physician opinion. Use our independent assessments to validate or challenge in-house assumptions
- Count on MattsonJack DaVinci’s tested epidemiology and market models to provide the background and direction you need
- Tap the expertise of dedicated MattsonJack DaVinci researchers and consultants
- Stay ahead of the curve regarding this rapidly developing market
Methodology MattsonJack DaVinci used a variety of techniques and methods to complete this report including: Surveys of 50 oncologists and hematologists in September 2006 Attendance and review of material from: - 40th Annual ASCO meeting; Atlanta-June 2006
- 48th Annual ASH meeting; Orlando-December 2006
- 31st ESMO Congress; Istanbul Turkey-September 2006
- 11th Annual EHA Congress; Amsterdam, The Netherlands-June 2006
- 9th International Symposium on Myelodysplastic Syndromes, Florence Italy -May 2007
- Research articles from scientific journals, and information from text books and websites (government and private organizations)
- Quantitative and qualitative techniques for analyzing and interpreting data as well as developing population and market forecasts
Table of Contents Download TOC in PDF
|
